Compare Gilead Sciences, Inc. (GILD) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Standard Lithium Ltd — how do they compare? Gilead Sciences, Inc. trades at $133.04 (market cap $163.51B), while Standard Lithium Ltd trades at $2.18 (market cap $551.38M). The key difference: Gilead Sciences, Inc. is far larger — about 296.5× Standard Lithium Ltd's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Standard Lithium Ltd pays none. Which is the better fit depends on your goals.
| GILD | SLI | |
|---|---|---|
Market Cap | $163.51B | $551.38M |
Sector | Health | Basic Materials |
52-Week High | $155.80 | $5.65 |
52-Week Low | $108.22 | $2.29 |
Enterprise Value | $178.05B | $410.57M |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
SLI trades at $2.22, down 3.9% in the last 24 hours, with a bearish technical signal from moving averages but bullish oscillators. The company reported a net loss of $48.40 million for 2025, with negative ROE and ROA, though it secured a $225 million DOE grant and is progressing toward a final investment decision for its Arkansas lithium project. Analyst consensus is unanimously bullish with 3 buy ratings.
The outlook hinges on successful project execution and lithium market dynamics, offering growth potential but carrying significant operational and financial risks due to current losses and high cash burn. Investors should weigh the strong analyst support against fundamental weaknesses and project timeline uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
